id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-268519-t15yvy5s	Pothen, Lucie	Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center	2020-06-12		.txt	text/plain	538	40	52	title: Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center Despite some encouraging preliminary clinical data (2,3), major concerns have been raised about the use of HCQ to treat COVID-19 (5), particularly regarding potential cardiac toxicity (i.e. QTc increase and risk of torsade de pointe). Repeat ECG was not systematically performed during HCQ treatment, except in case of drug-drug interaction which could potentially increase QTc (see foot note of Table1). The efficacy of HCQ and its combination with azithromycin on COVID-19 infection needs, of course, to be strengthened with further evidence from large randomized clinical trials. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study	./cache/cord-268519-t15yvy5s.txt	./txt/cord-268519-t15yvy5s.txt